Title
Vitamin D3 Supplementation for Heart Failure Patients
Double-Blind, Placebo-Controlled Trial of Vitamin D3 (Cholecalciferol) Supplementation for Heart Failure Patients
Phase
Phase 2Lead Sponsor
Heidi Moretti, MS, RDStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Heart Failure Vitamin D Deficiency Cardiomyopathy Congestive Heart FailureIntervention/Treatment
vitamin d3 ...Study Participants
40The purpose of this study is to determine if treatment with vitamin D3 of 10,000 International Units (IU) daily in vitamin D deficient patients for 6 months will improve B type natriuretic peptide (BNP), a marker of heart function, compared to placebo. The investigators also aim to determine if vitamin D helps cardiopulmonary function as evaluated by cardiopulmonary exercise test (CPX), laboratory values, strength, and quality of life in patients with stable congestive heart failure (Class II or III).
Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.
Inclusion Criteria: NYHA Heart Failure Class II or II, stable Vitamin D deficiency (32 ng/ml or less) No recent medication changes for 3 months Females of childbearing age must use effective contraceptive if they are sexually active Exclusion Criteria: Hypercalcemia Nephrolithiases Sarcoidosis Acute cardiac insufficiency Pregnancy Breastfeeding Any clinically unstable medical condition Supplements of greater than or equal to 1000 units of vitamin D per day